MOONLAKE IMMUNOTHERAPEUTICS Basic Shares Outstanding (Weighted Average)
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Basic Shares Outstanding (Weighted Average) of 73.92 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-10
- MOONLAKE IMMUNOTHERAPEUTICS weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 73.92M shares, a 16.80% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 71.27M shares, a 12.71% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 67.97M shares, a 7.76% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 63.37M shares, a 0.75% increase year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS weighted average number of shares outstanding, basic for fiscal 2025 was 64.46M shares, a 2.53% increase from fiscal 2024.
- MOONLAKE IMMUNOTHERAPEUTICS weighted average number of shares outstanding, basic for fiscal 2024 was 62.87M shares, a 27.99% increase from fiscal 2023.
- MOONLAKE IMMUNOTHERAPEUTICS weighted average number of shares outstanding, basic for fiscal 2023 was 49.12M shares, a 67.30% increase from fiscal 2022.
- MOONLAKE IMMUNOTHERAPEUTICS weighted average number of shares outstanding, basic for fiscal 2022 was 29.36M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 10 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 73.92M shares 10-Q · filed 2026-08-10 | 72.60M shares 10-Q · filed 2026-08-10 | 71.05M shares derived: average of 3 quarters · filed 2026-08-10 | 69.13M shares derived: average of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | 71.27M shares 10-Q · filed 2026-05-11 | 69.62M shares derived: average of 2 quarters · filed 2026-05-11 | 67.54M shares derived: average of 3 quarters · filed 2026-05-11 | 66.47M shares derived: average of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | 67.97M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 65.67M shares derived: average of 2 quarters · filed 2026-02-25 | 64.87M shares derived: average of 3 quarters · filed 2026-08-10 | 64.46M shares 10-K · filed 2026-02-25 | |
| 2025-09-30 | 63.37M shares 10-Q · filed 2025-11-05 | 63.33M shares derived: average of 2 quarters · filed 2026-08-10 | 63.30M shares 10-Q · filed 2025-11-05 | 63.24M shares derived: average of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | 63.28M shares 10-Q · filed 2026-08-10 | 63.26M shares 10-Q · filed 2026-08-10 | 63.20M shares derived: average of 3 quarters · filed 2026-08-10 | 63.12M shares derived: average of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | 63.23M shares 10-Q · filed 2026-05-11 | 63.15M shares derived: average of 2 quarters · filed 2026-05-11 | 63.07M shares derived: average of 3 quarters · filed 2026-05-11 | 63.02M shares derived: average of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | 63.07M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 62.98M shares derived: average of 2 quarters · filed 2026-02-25 | 62.95M shares derived: average of 3 quarters · filed 2026-02-25 | 62.87M shares 10-K · filed 2026-02-25 | |
| 2024-09-30 | 62.90M shares 10-Q · filed 2025-11-05 | 62.89M shares derived: average of 2 quarters · filed 2025-11-05 | 62.80M shares 10-Q · filed 2025-11-05 | 62.11M shares derived: average of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | 62.87M shares 10-Q · filed 2025-08-05 | 62.76M shares 10-Q · filed 2025-08-05 | 61.85M shares derived: average of 3 quarters · filed 2026-02-25 | 59.77M shares derived: average of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | 62.64M shares 10-Q · filed 2025-05-12 | 61.34M shares derived: average of 2 quarters · filed 2026-02-25 | 58.73M shares derived: average of 3 quarters · filed 2026-02-25 | 54.98M shares derived: average of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | 60.03M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 56.78M shares derived: average of 2 quarters · filed 2026-02-25 | 52.42M shares derived: average of 3 quarters · filed 2026-02-25 | 49.12M shares 10-K · filed 2026-02-25 | |
| 2023-09-30 | 53.52M shares 10-Q · filed 2024-11-07 | 48.62M shares derived: average of 2 quarters · filed 2024-11-07 | 45.49M shares 10-Q · filed 2024-11-07 | 44.06M shares derived: average of 4 quarters · filed 2025-02-26 | |
| 2023-06-30 | 43.72M shares 10-Q · filed 2024-08-07 | 41.40M shares 10-Q · filed 2024-08-07 | 40.91M shares derived: average of 3 quarters · filed 2025-02-26 | 39.91M shares derived: average of 4 quarters · filed 2025-02-26 | |
| 2023-03-31 | 39.06M shares 10-Q · filed 2024-05-07 | 39.51M shares derived: average of 2 quarters · filed 2025-02-26 | 38.65M shares derived: average of 3 quarters · filed 2025-02-26 | 37.79M shares derived: average of 4 quarters · filed 2025-02-26 | |
| 2022-12-31 | 39.95M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | 38.44M shares derived: average of 2 quarters · filed 2025-02-26 | 37.36M shares derived: average of 3 quarters · filed 2025-02-26 | 29.36M shares 10-K · filed 2025-02-26 | |
| 2022-09-30 | 36.93M shares 10-Q · filed 2023-11-14 | 36.06M shares derived: average of 2 quarters · filed 2023-11-14 | 25.83M shares 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | 35.20M shares 10-Q · filed 2023-08-10 | 20.19M shares 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | 5.01M shares 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | 7.84M shares 10-K · filed 2023-03-20 | ||||
| 2021-09-30 | 2.39M shares 10-Q · filed 2022-11-14 | 6.83M shares derived: average of 2 quarters · filed 2022-11-14 | 9.69M shares 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | 11.28M shares 10-Q · filed 2022-08-12 | 15.63M shares 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |